Combined treatment with a DNA demethylating agent, 5-aza-2′-deoxycytidine (5-aza-dC), and an EZH2 inhibitor, GSK126, induced marked re-expression of genes with the dual modification and showed an additive inhibitory effect on cancer cell growth in vitro, suggesting the possible therapeutic application of the inhibitors used [47]. The gene discussed is EZH2; the disease is cancer.